Last reviewed · How we verify
TNF Inhibitor (W12-W48)
TNF Inhibitor (W12-W48) is a TNF inhibitor Small molecule drug developed by University Hospital, Montpellier. It is currently in Phase 3 development for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Ankylosing spondylitis.
TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce systemic inflammation and immune-mediated tissue damage.
TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce systemic inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Ankylosing spondylitis.
At a glance
| Generic name | TNF Inhibitor (W12-W48) |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Drug class | TNF inhibitor |
| Target | TNF (tumor necrosis factor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF is a pro-inflammatory cytokine central to inflammatory and autoimmune diseases. TNF inhibitors work by binding to and neutralizing TNF or blocking its receptors (TNFR1/TNFR2), thereby suppressing the inflammatory cascade. This reduces immune cell activation, cytokine production, and tissue inflammation in conditions driven by TNF overexpression.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Ankylosing spondylitis
- Psoriasis and psoriatic arthritis
Common side effects
- Increased infection risk (including tuberculosis, opportunistic infections)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Autoimmune phenomena (lupus-like syndrome)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNF Inhibitor (W12-W48) CI brief — competitive landscape report
- TNF Inhibitor (W12-W48) updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI
Frequently asked questions about TNF Inhibitor (W12-W48)
What is TNF Inhibitor (W12-W48)?
How does TNF Inhibitor (W12-W48) work?
What is TNF Inhibitor (W12-W48) used for?
Who makes TNF Inhibitor (W12-W48)?
What drug class is TNF Inhibitor (W12-W48) in?
What development phase is TNF Inhibitor (W12-W48) in?
What are the side effects of TNF Inhibitor (W12-W48)?
What does TNF Inhibitor (W12-W48) target?
Related
- Drug class: All TNF inhibitor drugs
- Target: All drugs targeting TNF (tumor necrosis factor)
- Manufacturer: University Hospital, Montpellier — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Indication: Drugs for Ankylosing spondylitis
- Compare: TNF Inhibitor (W12-W48) vs similar drugs
- Pricing: TNF Inhibitor (W12-W48) cost, discount & access